Today: 21 May 2026
Browse Category

NSE:SBIN.NS 2 December 2025 - 2 April 2026

Sensex, Nifty Reverse After Rs 10 Lakh Crore Wipeout as Rupee Jumps, Iran Oil Fears Linger

Sensex, Nifty Reverse After Rs 10 Lakh Crore Wipeout as Rupee Jumps, Iran Oil Fears Linger

Indian shares rebounded from steep early losses Thursday, with the Sensex closing up 0.25% and the Nifty 50 rising 0.15% after the Reserve Bank of India’s intervention triggered the rupee’s biggest one-day gain since 2013. The rupee jumped 1.8% to close at 93.10 per dollar. Banks led early declines, and India’s March manufacturing PMI fell to 53.9 from 56.9. Brent crude hovered near $109 a barrel.
2 April 2026
····
Sensex Today: Why India Stocks Are Sliding as Oil Nears $113 and Rupee Hits Record Low

Sensex Today: Why India Stocks Are Sliding as Oil Nears $113 and Rupee Hits Record Low

The BSE Sensex dropped 1,958 points, or 2.63%, to 72,574.92 by midday Monday, while the Nifty 50 hit its lowest since April 2025. Brent crude hovered near $113 a barrel, the rupee slid to a record 93.94 per dollar, and foreign investors have pulled $9.57 billion from Indian equities in March. HDFC Bank fell 2.5%, and State Bank of India lost 3.6%.
23 March 2026
···
India’s Big Bank Debate and Kerala’s Stray Dog ABC Drive: Key Updates and What’s Next (December 12, 2025)

India’s Big Bank Debate and Kerala’s Stray Dog ABC Drive: Key Updates and What’s Next (December 12, 2025)

Indian banks are pressing the Reserve Bank of India to double the cap on merger-and-acquisition financing, seeking greater scale amid rising deal activity, The Economic Times reported Friday. Local governments are racing to comply with a Supreme Court order to keep stray dogs out of sensitive areas, facing infrastructure limits and protests from animal groups, according to multiple outlets.
12 December 2025

Stock Market Today

  • Regional Banks Q1 Earnings Review: Merchants Bancorp Vs Peers
    May 20, 2026, 8:58 PM EDT. Regional banks faced mixed Q1 results with share prices down 2.9% on average. Merchants Bancorp (NASDAQ:MBIN), focused on low-risk, government-backed lending, reported $175.2 million in revenue, up 20.1% year on year but missed net interest income estimates. Its stock dropped 9% post-earnings. UMB Financial (NASDAQ:UMBF) outperformed with $744.8 million revenue, up 29.3%, exceeding analyst forecasts by 5.4%. Regional banks benefit from rising interest rates and digital transformation, but challenges from fintech competition, deposit outflows, credit risk, and regulatory costs remain, alongside recent stability concerns in commercial real estate exposure.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop